Interview: Regis Cebe, Principal Scientist II, Novartis
Interview: Roberto De Luca, Head of therapeutic Antibodies, Philochem/Philogen
Interview: Jeanette Leusen, Head of the Immunotherapy Group and UMAB, UMCU
Model Risk Management for the Machine Learning Era
Collaborative standardisation and disruptive innovation: summary paper developed by Haris Tsilikas, Max Plank Institute, for 4iP Council.
Why researchers need an IP strategy
